allodynia from glp-1 Drugs: New Reports of Dysesthesia and Benefit-Risk Assessment of GLP-1 Receptor
Description
A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells
The clinical trial outcomes and FDA guidelines differ for these medications
Secondary endpoints Weight loss A difference in weight loss was already seen at M3 (9.2% [3.6] vs
Nausea, vomiting, diarrhea, and reduced appetite may make it easier to consume fewer fluids throughout the day
Rapid economic development, rising healthcare expenditure, growing diabetes epidemic and increasing focus of international players on emerging Asian markets can drive the market growth
